Skip to main content
. 2022 Nov 30;13:1018027. doi: 10.3389/fneur.2022.1018027

Figure 3.

Figure 3

Network map for hypoglycemic drugs (HD) with placebo in improving MMSE score. (A) ADAS-Cog score, (B) ADCS-ADL scale score, (C) Lines connect the interventions that have been studied in head-to-head comparisons in eligible RCTs. The width of the lines represents the total number of RCTs for each pairwise comparison. The size of each node is proportional to the number of randomized participants. Metformin (MTN), Pioglitazone (PLZ), Intranasal insulin 20 IU (ITSN20), Intranasal insulin 40 IU (ITSN40), Rosiglitazone 2 mg (RLZ2), Rosiglitazone 4 mg (RLZ4), Rosiglitazone 8 mg (RLZ8), Rosiglitazone 10 mg (RLZ10), Glucagon-like peptide-1 (GLP-1), Dipeptidyl peptidase 4 inhibitor (DPP-4).